We’re thrilled to share that Shoulder Innovations has been named one of BONEZONE’s Top 10 Orthopedic Companies to Watch in 2026.
Being selected for this list is an honor and a testament to the hard work of our entire team. As a newly-public company experiencing rapid growth, this recognition continues to validate our mission to transform shoulder replacement through innovation, efficiency, and a focus on solving real challenges for all stakeholders.
BONEZONE called us “one of the most interesting growth stories in the upper extremity space” — and we’re excited to continue Reaching Further™ in 2026.
Here’s what they had to say:
Shoulder Innovations is emerging as one of the most interesting growth stories in the upper extremity space. The newly-public company expects full-year revenue of $45 to $46 million, representing growth of more than 30%. A key differentiator for the company is its focus on developing solutions that promote efficiency in the ASC setting.
CEO Rob Ball has made streamlined instrumentation a core strategic pillar, with the goal of enabling total and reverse shoulder procedures using just two instrument trays. For ASCs constrained by reprocessing capacity, that reduction can mean the difference between performing one procedure per day and completing several.
Shoulder Innovations is also pushing into robotics. The company announced a partnership with Interventional Systems to develop a portable, shoulder-specific micro-robotic solution that’s designed to integrate with its ProVoyance® platform.
The unit is intended to be mobile, cost-efficient and well-suited to ASC environments, addressing many of the barriers that have slowed robotic adoption in shoulder replacement surgery. In November, Shoulder Innovations announced the full commercial launch of the InSet 70 for the I-Series humeral stem product line. With continued product line expansion, the company is positioned to capitalize on the growing shoulder replacement and ASC markets.